Vax-Beacon · Interactive Case Report Viewer

Temporal proximity within the strong causal window (5 days) combined with an established causal association between mRNA COVID-19 vaccines and myocarditis (NAM 2024). The competing viral etiology hypothesis lacked supporting evidence (no viral panel performed, NCI below threshold). Classification determined by deterministic code; this explanation generated by LLM.

3A Observer: Identified hemodynamic compromise (hypotension, tachycardia), severe systolic dysfunction (EF 35–45%), markedly elevated BNP (1389), high fever (107°F), GI involvement.
3B Matcher: Matched giant_cell_myocarditis subtype: rapid heart failure + hemodynamic instability pattern. Also flagged viral_etiology: prior COVID-19 + fever.
3C Assessor: Giant cell pattern plausible given severe presentation with rapid onset heart failure and hemodynamic compromise. Age and severity consistent.
3D Calculator: NCI = 0.60. Above decisional threshold. Strong alternative diagnosis identified.

Temporal plausibility exists but is borderline (12 days, outside the strong 0–7 day causal window). A competing alternative diagnosis (giant cell myocarditis) scored above the NCI threshold at 0.60, driven by the severity pattern: rapid heart failure, hemodynamic instability, and markedly elevated BNP. The prior COVID-19 infection (2 months prior) adds additional diagnostic complexity. Classification: indeterminate pending further investigation.

Despite temporal proximity (4 days) and plausible biological mechanism, pericarditis is not currently listed as a confirmed adverse event of mRNA COVID-19 vaccines in NAM 2024 evidence review. Without a recognized causal association and without a competing alternative diagnosis, the WHO algorithm classifies this as coincidental. The prior COVID-19 infection (April 2020) may represent a delayed post-infectious pericarditis — this is captured in Stage 6 guidance.

Young male with post-vaccination chest pain diagnosed as myocarditis but lacks any objective cardiac testing. Basic troponin and ECG could rapidly upgrade this to Level 2–3 classification.

14-year-old male developed Brighton Level 1 myocarditis 3 days after second Pfizer vaccine, meeting A1 classification criteria with strong temporal relationship. Missing viral testing data represents only minor gap.

The inter-dose viral illness creates diagnostic ambiguity. Symptoms (cough, fatigue, diarrhea) are consistent with a viral prodrome that could independently cause myocarditis. However, NCI 0.4 is below the “definite alternative” threshold — viral etiology is possible but not confirmed without testing.

Temporal association supports vaccine causation (3 days, strong causal window), but inter-dose viral illness creates diagnostic ambiguity. NCI 0.4 indicates moderate alternative etiology — not enough to rule out vaccine, not enough to confirm it. Targeted viral testing could resolve this classification.

Severe presentation with CHF and non-sustained VT is atypical for vaccine-associated myocarditis (which typically presents with chest pain and mild troponin elevation, not heart failure or arrhythmias). This pattern is highly characteristic of giant cell myocarditis (GCM). NCI = 1.0 indicates definite alternative etiology.

Severe presentation with CHF and VT 50 days post-vaccination strongly suggests giant cell myocarditis rather than vaccine-associated myocarditis. URGENT escalation — GCM carries >70% mortality without immunosuppression.